Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
October 29 2020 - 7:00AM
- Immatics’ first TCR Bispecific program IMA401 delivers
preclinical proof-of-concept demonstrating complete remissions of
transplanted human tumors in mice and favorable CMC
characteristics
- The IMA401 target, an HLA-A*02-bound peptide derived
both from MAGEA4 and MAGEA8, shows >5-fold higher target peptide
levels on cancer cells than a commonly used target peptide derived
from MAGEA4
- Immatics continues to anticipate submission of an IND
application for IMA401 by the end of 2021
Tuebingen, Germany and Houston, Texas,
October 29, 2020 – Immatics N.V. (NASDAQ: IMTX,
“Immatics”), a clinical-stage biopharmaceutical company active in
the discovery and development of T cell redirecting cancer
immunotherapies, today announced a preclinical data update on
IMA401, its lead T cell receptor (TCR) Bispecifics Program. IMA401
is the first product candidate from Immatics’ TCR Bispecifics
pipeline, called TCER™ (T Cell Engaging Receptor), and directed
against the cancer target MAGEA4/8. Immatics demonstrated specific
targeting and T cell recruitment to target-positive tumors by its
proprietary TCR Bispecific molecule, leading to complete remissions
of human-derived tumors in xenograft mouse models. The data will be
presented at the digital European Antibody Congress 2020 on
November 2.
Preclinical data
highlights:
- IMA401 TCER™ targets a peptide derived from the
melanoma-associated antigen 4 or 8 (“MAGEA4/8”); the target peptide
is highly prevalent in several solid tumor types including squamous
non-small-cell lung carcinoma (sq NSCLC), head and neck squamous
cell carcinoma (HNSCC) bladder, uterine, esophageal and ovarian
carcinomas, as well as melanoma, sarcoma subtypes and other solid
cancer types
- IMA401 TCER™ can kill tumor cells in vitro with MAGEA4/8
peptide levels similar to levels found in cancer patients
- IMA401 TCER™ shows a minimum of 1,000-fold therapeutic window
between normal tissue cell reactivity and tumor cell reactivity in
vitro
- IMA401 TCER™ demonstrates consistent tumor regression including
complete responses in two tumor xenograft mouse studies (including
patient-derived PDX models) treated once weekly at low doses
- IMA401 TCER™ molecule shows favorable pharmacokinetics with
terminal half-life of 10-11 days in mice and positive purity and
stability characteristics with high production yields
- IMA401 TCER™ targets an HLA-A*02-bound peptide, which is
derived from two different cancer-associated proteins, MAGEA4 and
MAGEA8 and shows a >5-fold higher peptide copy number per tumor
cell than a commonly used MAGEA4 target peptide based on
quantitative mass spectrometry data generated by Immatics´
XPRESIDENT® platform
Carsten Reinhardt, MD, PhD, Chief Development
Officer at Immatics, commented: “We continue to be enthusiastic
about our first TCR Bispecific candidate and the preclinical
proof-of-concept data we have generated. We look forward to
advancing this novel treatment modality towards clinical
development. This represents a new therapeutic opportunity in
addition to our adoptive cell therapy programs for cancer patients
at different disease stages and with different types of solid
tumors.”
For the IMA401 TCER™ program, Immatics is
continuing the manufacturing development and the generation of the
IND-enabling data package. Immatics expects to submit an
Investigational New Drug (IND) application to the US Food and Drug
Administration (FDA) or the European Authorities for the IMA401
program by the end of 2021.
The full presentation will be available on
Monday, November 2, 3:20pm CET on Immatics’ website using this
link.
About
TCER™Immatics’ TCER™ molecules are
antibody-like “off-the-shelf” biologics that leverage the body’s
immune system by redirecting and activating T cells towards cancer
cells expressing a specific tumor target. To do so, the proprietary
biologics are engineered to have two binding regions. The first
region contains an affinity- and stability-improved TCR that binds
specifically to the cancer target on the cell surface presented by
a human leukocyte antigen (HLA) molecule. The second region is
derived from an antibody domain that recruits endogenous T cells to
the tumor to become activated. The design of the TCER™ molecules
enables the activation of any T cell in the body to attack the
tumor, regardless of the T cells’ intrinsic specificity. In
addition, the TCER™ molecule has a Fc-part conferring stability,
half-life extension and manufacturability.
Notes to Editors
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
For regular updates about Immatics, visit
www.immatics.com. You can also follow us on Twitter and
LinkedIn.
Forward-Looking
Statements:Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the Securities and Exchange Commission (SEC).
Nothing in this presentation should be regarded as a representation
by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as
of the date they are made. Immatics undertakes no duty to update
these forward-looking statements.
For more information, please
contact:
For media enquiries |
Investor Relations Contact |
Gretchen Schweitzer or Jacob Verghese, PhD |
John Graziano |
Trophic Communications |
Solebury Trout |
Phone: +49 89 2388 7731 |
Phone: +1 646-378-2942 |
immatics@trophic.eu |
jgraziano@soleburytrout.com |
Immatics N.V. |
Investor Relations Contact |
Anja Heuer |
Jordan Silverstein |
Corporate Communications |
Head of Strategy |
Phone: +49 89 540415-606 |
Phone: +1 281-810-7545 |
media@immatics.com |
InvestorRelations@immatics.com |
- IMA401 preclinical data presentation_ENG
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024